Amicus Therapeutics Company Profile (NASDAQ:FOLD)

About Amicus Therapeutics

Amicus Therapeutics logoAmicus Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the discovery and development of therapies to treat a range of rare and orphan diseases. Its lead product candidate, migalastat HCl (Galafold), is an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease, which is a type of lysosomal storage disorder (LSD). It has completed two Phase III global registration studies (Study 011 and Study 012) of migalastat monotherapy. It is also engaged in Phase III clinical development of a topical cream, SD-101, for the treatment of the genetic connective tissue disorder Epidermolysis Bullosa. It has also initiated a clinical study in patients with Pompe disease, a LSD to investigate its treatment paradigm that consists of ATB200, which is an engineered recombinant human acid alpha-glucosidase enzyme with an optimized carbohydrate structure to enhance uptake, co-administered with AT2221, to improve activity and stability.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: FOLD
  • CUSIP: 03152W10
Key Metrics:
  • Previous Close: $6.05
  • 50 Day Moving Average: $5.74
  • 200 Day Moving Average: $6.65
  • 52-Week Range: $4.41 - $9.83
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -5.05
  • P/E Growth: -0.12
  • Market Cap: $848.26M
  • Outstanding Shares: 142,326,000
  • Beta: 1.55
  • Return on Equity: -55.51%
  • Return on Assets: -20.56%
  • Current Ratio: 2.59%
  • Quick Ratio: 2.55%
Additional Links:
Companies Related to Amicus Therapeutics:

Analyst Ratings

Consensus Ratings for Amicus Therapeutics (NASDAQ:FOLD) (?)
Ratings Breakdown: 1 Hold Rating, 7 Buy Ratings
Consensus Rating:Buy (Score: 2.88)
Consensus Price Target: $12.00 (101.34% upside)

Analysts' Ratings History for Amicus Therapeutics (NASDAQ:FOLD)
DateFirmActionRatingPrice TargetDetails
1/31/2017Robert W. BairdUpgradeOutperformView Rating Details
12/8/2016Cowen and CompanySet Price TargetBuy$12.00View Rating Details
11/30/2016Leerink SwannReiterated RatingOutperform$17.00 -> $15.00View Rating Details
11/30/2016J P Morgan Chase & CoReiterated RatingOverweight$12.00 -> $11.00View Rating Details
11/29/2016Chardan CapitalReiterated RatingBuy$15.00 -> $16.00View Rating Details
5/18/2016Bank of America CorpInitiated CoverageBuy$10.00View Rating Details
3/30/2016Goldman Sachs Group, Inc. (The)Initiated CoverageNeutral$10.00View Rating Details
3/8/2016Janney Montgomery ScottUpgradeNeutral -> Buy$10.00 -> $12.00View Rating Details
6/16/2015B. RileyBoost Price TargetBuy$14.00 -> $17.50View Rating Details
(Data available from 2/25/2015 forward)


Earnings History for Amicus Therapeutics (NASDAQ:FOLD)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/7/2016Q3($0.34)($0.33)$1.71 million$2.10 millionViewListenView Earnings Details
8/9/2016Q2($0.33)($0.40)$0.17 millionViewN/AView Earnings Details
5/3/2016Q1($0.34)($0.35)ViewListenView Earnings Details
2/26/2016Q4($0.31)($1.20)ViewListenView Earnings Details
11/3/2015Q3($0.25)($0.32)ViewN/AView Earnings Details
8/5/2015Q215($0.24)($0.27)ViewN/AView Earnings Details
5/5/2015Q115($0.21)($0.25)ViewN/AView Earnings Details
3/3/2015Q414($0.18)($0.24)ViewN/AView Earnings Details
11/6/2014($0.21)($0.22)ViewN/AView Earnings Details
8/7/2014($0.23)($0.31)ViewN/AView Earnings Details
5/5/2014($0.24)($0.25)ViewN/AView Earnings Details
3/3/2014Q4 13($0.32)($0.22)ViewN/AView Earnings Details
11/11/2013Q3($0.32)($0.29)ViewN/AView Earnings Details
8/7/2013Q2 2013($0.35)($0.31)ViewN/AView Earnings Details
5/9/2013Q1 2013($0.30)($0.34)ViewN/AView Earnings Details
11/5/2012Q312($0.24)($0.31)$8.82 million$5.80 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Amicus Therapeutics (NASDAQ:FOLD)
Current Year EPS Consensus Estimate: $-1.40 EPS
Next Year EPS Consensus Estimate: $-1.18 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q3 20161($0.31)($0.31)($0.31)
Q4 20161($0.35)($0.35)($0.35)
Q1 20171($0.36)($0.36)($0.36)
Q2 20171($0.37)($0.37)($0.37)
Q3 20171($0.37)($0.37)($0.37)
Q4 20171($0.37)($0.37)($0.37)
(Data provided by Zacks Investment Research)


Dividend History for Amicus Therapeutics (NASDAQ:FOLD)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading History for Amicus Therapeutics (NASDAQ:FOLD)
Insider Ownership Percentage: 3.40%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
1/13/2017Hung DoInsiderSell25,000$6.00$150,000.00View SEC Filing  
12/30/2016Perceptive Advisors LlcMajor ShareholderBuy94,750$4.96$469,960.00View SEC Filing  
12/29/2016Perceptive Advisors LlcMajor ShareholderBuy142,125$4.87$692,148.75View SEC Filing  
12/23/2016Perceptive Advisors LlcMajor ShareholderBuy85,275$4.81$410,172.75View SEC Filing  
12/22/2016Perceptive Advisors LlcMajor ShareholderBuy189,500$4.51$854,645.00View SEC Filing  
11/9/2016Daphne QuimiSVPSell8,546$8.00$68,368.00View SEC Filing  
11/1/2016Hung DoInsiderSell25,000$7.00$175,000.00View SEC Filing  
10/3/2016Hung DoInsiderSell25,000$7.25$181,250.00View SEC Filing  
9/20/2016William D Baird IIICFOSell20,500$8.00$164,000.00View SEC Filing  
9/6/2016Hung DoInsiderSell25,000$7.00$175,000.00View SEC Filing  
8/25/2016Perceptive Advisors LlcInsiderSell1,100,000$6.81$7,491,000.00View SEC Filing  
8/4/2016Jay BarthInsiderSell10,458$7.00$73,206.00View SEC Filing  
7/27/2016Jay BarthInsiderSell20,916$7.00$146,412.00View SEC Filing  
6/2/2016Ellen RosenbergGeneral CounselBuy15,000$7.67$115,050.00View SEC Filing  
11/10/2015Margaret G McglynnDirectorBuy10,000$10.27$102,700.00View SEC Filing  
10/7/2015Perceptive Advisors LlcMajor ShareholderBuy50,000$6.27$313,500.00View SEC Filing  
10/6/2015Perceptive Advisors LlcMajor ShareholderBuy750,000$6.71$5,032,500.00View SEC Filing  
10/1/2015Kenneth PeistVPSell10,000$13.14$131,400.00View SEC Filing  
9/21/2015Bradley L. CampbellCOOSell13,001$16.78$218,156.78View SEC Filing  
9/21/2015William D. Baird IIICFOSell15,236$16.78$255,660.08View SEC Filing  
9/15/2015Hung DoInsiderSell25,000$17.75$443,750.00View SEC Filing  
9/14/2015Daphne QuimiVPSell2,500$18.08$45,200.00View SEC Filing  
7/16/2015John F CrowleyCEOSell16,025$16.00$256,400.00View SEC Filing  
7/14/2015John F CrowleyCEOSell142,250$15.03$2,138,017.50View SEC Filing  
7/13/2015Glenn SblendorioDirectorSell10,000$15.00$150,000.00View SEC Filing  
7/13/2015John F CrowleyCEOSell7,750$15.01$116,327.50View SEC Filing  
7/13/2015Ken ValenzanoSVPSell15,000$15.00$225,000.00View SEC Filing  
7/8/2015Dipal DoshiSVPSell6,250$13.87$86,687.50View SEC Filing  
7/1/2015Jayne GershkowitzSVPSell10,649$13.97$148,766.53View SEC Filing  
7/1/2015Kenneth PeistVPSell10,000$13.98$139,800.00View SEC Filing  
6/23/2015Donald J Hayden JrDirectorSell55,000$14.01$770,550.00View SEC Filing  
6/22/2015Jeff CastelliSVPSell18,981$13.94$264,595.14View SEC Filing  
6/19/2015Bradley L CampbellCOOSell13,000$13.26$172,380.00View SEC Filing  
6/19/2015Enrique DiloneSVPSell14,045$13.26$186,236.70View SEC Filing  
6/19/2015William D Baird IIICFOSell15,235$13.26$202,016.10View SEC Filing  
6/15/2015Jeff CastelliSVPSell7,377$14.17$104,532.09View SEC Filing  
6/15/2015Julie YuVPSell8,195$14.17$116,123.15View SEC Filing  
6/8/2015Jeff CastelliSVPSell17,312$12.87$222,805.44View SEC Filing  
6/8/2015John F CrowleyCEOSell55,000$13.01$715,550.00View SEC Filing  
5/11/2015Jeff CastelliSVPSell10,000$10.84$108,400.00View SEC Filing  
5/11/2015Kenneth PeistVPSell12,500$10.84$135,500.00View SEC Filing  
5/11/2015William D Baird IIICFOSell24,800$10.84$268,832.00View SEC Filing  
4/15/2015Glenn SblendorioDirectorSell20,000$12.50$250,000.00View SEC Filing  
4/15/2015Ken ValenzanoVPSell5,000$12.50$62,500.00View SEC Filing  
4/10/2015John F CrowleyCEOSell11,678$12.00$140,136.00View SEC Filing  
4/1/2015Jeff CastelliVPSell9,489$10.69$101,437.41View SEC Filing  
1/5/2015Jeff CastelliVPSell4,667$9.00$42,003.00View SEC Filing  
12/4/2014John F CrowleyCEOSell89,000$8.36$744,040.00View SEC Filing  
11/25/2014Bradley L CampbellCOOSell7,250$8.00$58,000.00View SEC Filing  
11/25/2014Jeff CastelliVPSell8,103$8.00$64,824.00View SEC Filing  
11/25/2014William D Baird IIICFOSell10,000$8.00$80,000.00View SEC Filing  
11/19/2014Perceptive Advisors LlcMajor ShareholderBuy2,100,000$6.50$13,650,000.00View SEC Filing  
10/27/2014Plc GlaxosmithklineMajor ShareholderSell11,315,825$5.29$59,860,714.25View SEC Filing  
10/3/2014Jeff CastelliVPSell8,552$7.00$59,864.00View SEC Filing  
10/3/2014William D Baird IIICFOSell10,000$7.00$70,000.00View SEC Filing  
10/2/2014Julie YuVPSell4,759$5.99$28,506.41View SEC Filing  
9/29/2014Daphne QuimiVPSell10,738$6.10$65,501.80View SEC Filing  
9/29/2014William D Baird IIICFOSell25,311$6.09$154,143.99View SEC Filing  
8/27/2014Glenn SblendorioDirectorSell10,000$6.50$65,000.00View SEC Filing  
8/27/2014Jayne GershkowitzVPSell5,000$7.00$35,000.00View SEC Filing  
8/25/2014Bradley L CampbellCOOSell7,000$6.00$42,000.00View SEC Filing  
8/25/2014Jayne GershkowitzVPSell5,000$6.00$30,000.00View SEC Filing  
8/20/2014Bradley L CampbellCOOSell18,750$5.40$101,250.00View SEC Filing  
8/20/2014Enrique DiloneVPSell12,810$5.40$69,174.00View SEC Filing  
6/30/2014Perceptive Advisors LlcMajor ShareholderBuy4,000,000$3.50$14,000,000.00View SEC Filing  
11/20/2013Plc Glaxosmithklinemajor shareholderBuy1,500,000$2.00$3,000,000.00View SEC Filing  
3/15/2013Sol J BarerDirectorBuy25,000$3.40$85,000.00View SEC Filing  
11/13/2012Joan WinterbottomSVPBuy1,665$4.54$7,559.10View SEC Filing  
(Data available from 1/1/2013 forward)


Latest Headlines for Amicus Therapeutics (NASDAQ:FOLD)
News IconKeeping Tabs on Levels for Amicus Therapeutics, Inc. (NASDAQ:FOLD) - Midway Monitor (NASDAQ:FOLD) - February 24 at 4:35 PM
News IconEarnings Guidance on Amicus Therapeutics, Inc.(FOLD) - Energy Index (NASDAQ:FOLD) - February 23 at 5:17 PM
News IconAre Analysts Optimistic About Where Amicus Therapeutics, Inc. (NASDAQ:FOLD) is Heading? - Winfield Review (NASDAQ:FOLD) - February 22 at 10:34 PM
News IconEPS Of Amicus Therapeutics, Inc. (NASDAQ:FOLD) At $-0.3 - Stock Observer (NASDAQ:FOLD) - February 22 at 10:34 PM
News IconChecking the Levels on Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) - Baldwin Journal (NASDAQ:FOLD) - February 22 at 5:32 PM
News IconThe Hain Celestial Group, Inc. (HAIN), Amicus Therapeutics, Inc. (FOLD) Stock Eyes Ahead of Earnings - The USA Commerce (NASDAQ:FOLD) - February 22 at 5:32 PM
News IconWhich insiders are trading Amicus Therapeutics, Inc. (FOLD)? | Post ... - Post Analyst (NASDAQ:FOLD) - February 22 at 5:32 PM logoAmicus Therapeutics : Presents Additional Positive Preliminary Phase 1/2 Data at WORLDSymposium 2017 (NASDAQ:FOLD) - February 17 at 8:59 AM logoAmicus Therapeutics : Highlights New Fabry Program Data at WORLDSymposium 2017 (NASDAQ:FOLD) - February 16 at 10:14 PM logoAmicus Posts Positive Update for Migalastat (FOLD) (NASDAQ:FOLD) - February 16 at 5:14 PM logoAmicus Therapeutics Presents Important New Scientific Findings and Preclinical Data for Pompe Program at WORLDSymposium™ 2017 (NASDAQ:FOLD) - February 16 at 5:14 PM logoAmicus Therapeutics Updates Migalastat Drug (NASDAQ:FOLD) - February 16 at 5:14 PM logoAmicus Therapeutics Presents Additional Positive Preliminary Phase 1/2 Data at WORLDSymposium™ 2017 (NASDAQ:FOLD) - February 16 at 5:14 PM logo3:00 am Amicus Therapeutics presents additional positive preliminary Phase 1/2 Data; demonstrates improving trends in majority of patients (NASDAQ:FOLD) - February 16 at 5:14 PM logoAMICUS THERAPEUTICS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits (NASDAQ:FOLD) - February 16 at 5:14 PM logo3:08 am Amicus Therapeutics reports new positive data analyses for the oral small molecule pharmacological chaperone migalastat HCl for Fabry disease (NASDAQ:FOLD) - February 15 at 4:21 AM logoAmicus Therapeutics Highlights New Fabry Program Data at WORLDSymposium™ 2017 (NASDAQ:FOLD) - February 14 at 11:21 PM
News IconAmicus Therapeutics, Inc. (NASDAQ:FOLD) PT Suggests Stock Is Worth Around $11.06 (NASDAQ:FOLD) - February 14 at 6:20 PM
News IconShares to Watch: Indicator Update on Amicus Therapeutics Inc. (FOLD) - Baldwin Journal (NASDAQ:FOLD) - February 13 at 6:07 PM
News IconMovers to Watch Sprint Corp (NYSE:S), Amicus Therapeutics, Inc. (NASDAQ:FOLD) - Financial Breaking News (NASDAQ:FOLD) - February 13 at 6:07 PM
News IconNews Impact Score Of Amicus Therapeutics, Inc. (NASDAQ:FOLD) At 0 - Stock Observer (NASDAQ:FOLD) - February 13 at 6:07 PM logoAMICUS THERAPEUTICS INC Files SEC form 8-K, Change in Directors or Principal Officers (NASDAQ:FOLD) - February 9 at 5:53 PM logoStocks on the Move: Amicus Therapeutics, Inc. (FOLD), NRG Energy, Inc. (NRG), Aramark (ARMK) - iStreetWire (NASDAQ:FOLD) - February 8 at 5:48 PM
News IconAmicus Therapeutics, Inc. (NASDAQ:FOLD) has 1 year Price Target of $11.06 - The Newburgh Press (NASDAQ:FOLD) - February 7 at 6:30 PM logoAmicus Therapeutics May Still Have A Story - Seeking Alpha (NASDAQ:FOLD) - February 7 at 6:30 PM logoThe Biotech Market Grows as Demand for New Therapeutics Increases (NASDAQ:FOLD) - February 6 at 11:19 AM
News IconInteresting FOLD Call Options For February 17th (NASDAQ:FOLD) - February 6 at 11:19 AM logoAmicus Therapeutics to Present at the Leerink Partners 6th Annual Global Healthcare Conference (NASDAQ:FOLD) - February 6 at 11:19 AM logoWorth Watching Stocks: Amicus Therapeutics, Inc. (FOLD), NiSource Inc. (NI), H&R Block, Inc. (HRB) - iStreetWire (NASDAQ:FOLD) - February 2 at 5:49 PM
News IconEarnings Forecast Research on Amicus Therapeutics, Inc. (FOLD) - Highland Mirror (NASDAQ:FOLD) - February 1 at 10:57 PM
News IconWhat are Brokerage Firms Saying About Amicus Therapeutics, Inc. (NASDAQ:FOLD)? - Aiken Advocate (NASDAQ:FOLD) - January 30 at 5:57 PM
News IconAmicus Therapeutics, Inc. 75.4% Potential Upside Now Implied by Robert W. Baird (NASDAQ:FOLD) - January 27 at 7:04 PM
News IconAmicus Therapeutics, Inc. (NASDAQ:FOLD) Quarterly EPS Projection At $-0.3 - Stock Observer (NASDAQ:FOLD) - January 25 at 11:45 PM
News IconEarnings in Full Force, Analysts Take Aim at Amicus Therapeutics, Inc. (NASDAQ:FOLD) - Wall Street Beacon (NASDAQ:FOLD) - January 25 at 11:45 PM logoAmicus Therapeutics, General Motors, Broadcom Upgraded (NASDAQ:FOLD) - January 25 at 3:58 AM
News IconRobert W. Baird Just Issued " Outperform" Rating on Amicus Therapeutics (FOLD) (NASDAQ:FOLD) - January 25 at 3:58 AM logoAmicus Therapeutics upgraded by Robert W. Baird (NASDAQ:FOLD) - January 25 at 3:58 AM
News IconErratic Volume Takes A Hold of This Stock: Amicus Therapeutics, Inc. (NASDAQ:FOLD) - Wall Street Beacon (NASDAQ:FOLD) - January 24 at 10:57 PM logoAmicus Therapeutics (FOLD) Announces Presentations, Posters at WORLDSymposium - (NASDAQ:FOLD) - January 24 at 5:55 PM logoAmicus Therapeutics Upgraded To Outperform; Overhangs Are Removed With Catalysts Ahead (NASDAQ:FOLD) - January 24 at 10:54 AM
News IconNews Impact Score Of Amicus Therapeutics, Inc. (NASDAQ:FOLD) At 85 - Stock Observer (NASDAQ:FOLD) - January 23 at 5:38 PM
News IconMomentum Stocks in Concentration: Amicus Therapeutics, Inc. (NASDAQ:FOLD), Dean Foods Company (NYSE:DF) - The Newburgh Press (NASDAQ:FOLD) - January 23 at 5:38 PM
News IconThe Amicus Therapeutics Inc. (FOLD) Major Shareholder Buys $854645.00 in Stock (NASDAQ:FOLD) - January 22 at 10:09 PM logoOctober 20th Options Now Available For Amicus Therapeutics (FOLD) (NASDAQ:FOLD) - January 18 at 5:41 PM
News IconAmicus Therapeutics Inc FOLD Pharmaceuticals Healthcare Deals and Alliances Profile Prices from USD $250 (NASDAQ:FOLD) - January 18 at 5:41 PM
News IconStock Momentum Skidding to a Halt For Amicus Therapeutics, Inc. (NASDAQ:FOLD) - Wall Street Beacon (NASDAQ:FOLD) - January 17 at 10:58 PM
News IconInvestors Priming the Pump as Stock Reaches Most Volatile List: Amicus Therapeutics, Inc. (NASDAQ:FOLD) - Wall Street Beacon (NASDAQ:FOLD) - January 17 at 5:58 PM
News IconNews Impact Score Of Amicus Therapeutics, Inc. (NASDAQ:FOLD) Set At 50 - Stock Observer (NASDAQ:FOLD) - January 17 at 7:37 AM
News IconAmicus Therapeutics, Inc. (NASDAQ:FOLD) Quarterly Analysis - The Newburgh Press (NASDAQ:FOLD) - January 14 at 10:18 PM
News IconMarkets End Mostly Higher, How Did This Stock Fare: Amicus Therapeutics, Inc. (NASDAQ:FOLD) - Wall Street Beacon (NASDAQ:FOLD) - January 14 at 10:18 PM


What is Amicus Therapeutics' stock symbol?

Amicus Therapeutics trades on the NASDAQ under the ticker symbol "FOLD."

Where is Amicus Therapeutics' stock going? Where will Amicus Therapeutics' stock price be in 2017?

8 analysts have issued 12-month price objectives for Amicus Therapeutics' stock. Their forecasts range from $10.00 to $16.00. On average, they expect Amicus Therapeutics' share price to reach $12.00 in the next twelve months.

When will Amicus Therapeutics announce their earnings?

Amicus Therapeutics is scheduled to release their next quarterly earnings announcement on Friday, February, 24th 2017.

What are analysts saying about Amicus Therapeutics stock?

Here are some recent quotes from research analysts about Amicus Therapeutics stock:

  • According to Zacks Investment Research, "AMICUS THERAPEUTICS is a biopharmaceutical company developing novel, oral therapeutics known as pharmacological chaperones for the treatment of a range of human genetic diseases. Pharmacological chaperone technology involves the use of small molecules that selectively bind to and stabilize proteins in cells, leading to improved protein folding and trafficking, and increased activity. Amicus is initially targeting lysosomal storage disorders, which are severe, chronic genetic diseases with unmet medical needs. Amicus has completed Phase 2 clinical trials of Amigal(TM) for the treatment of Fabry disease and is conducting Phase 2 clinical trials of Plicera(TM) for the treatment of Gaucher disease. " (1/9/2017)

  • Cowen and Company analysts commented, "FOLD announced interim Pompe Ph1/2 ATB200/AT2221 PK/PD data from the first 4." (12/8/2016)

  • Bank of America Corp analysts commented, "phase 2b data was encouraging" and "doctors indicate Zorblisa could have wide use," (5/18/2016)

Who owns Amicus Therapeutics stock?

Amicus Therapeutics' stock is owned by many different of institutional and retail investors. Top institutional investors include FMR LLC (15.00%), Perceptive Advisors LLC (12.15%), Janus Capital Management LLC (4.84%), Palo Alto Investors LLC (4.50%), State Street Corp (4.02%) and Frazier Management LLC (1.83%). Company insiders that own Amicus Therapeutics stock include Bradley L Campbell, Daphne Quimi, Dipal Doshi, Donald J Hayden Jr, Ellen Rosenberg, Enrique Dilone, Glenn Sblendorio, Hung Do, Jay Barth, Jayne Gershkowitz, Jeff Castelli, John F Crowley, Julie Yu, Ken Valenzano, Kenneth Peist, Margaret G Mcglynn, Perceptive Advisors Llc and William D Baird III.

Who sold Amicus Therapeutics stock? Who is selling Amicus Therapeutics stock?

Amicus Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including Janus Capital Management LLC, Acuta Capital Partners LLC, Dimensional Fund Advisors LP, Franklin Resources Inc., Fred Alger Management Inc. and Metropolitan Life Insurance Co. NY. Company insiders that have sold Amicus Therapeutics stock in the last year include Daphne Quimi, Hung Do, Jay Barth, Perceptive Advisors Llc and William D Baird III.

Who bought Amicus Therapeutics stock? Who is buying Amicus Therapeutics stock?

Amicus Therapeutics' stock was purchased by a variety of institutional investors in the last quarter, including Perceptive Advisors LLC, Palo Alto Investors LLC, State Street Corp, Guggenheim Capital LLC, Tudor Investment Corp Et Al, FMR LLC and Brown Advisory Inc.. Company insiders that have bought Amicus Therapeutics stock in the last two years include Ellen Rosenberg, Margaret G Mcglynn and Perceptive Advisors Llc.

How do I buy Amicus Therapeutics stock?

Shares of Amicus Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Amicus Therapeutics stock cost?

One share of Amicus Therapeutics stock can currently be purchased for approximately $5.96.

Amicus Therapeutics (NASDAQ:FOLD) Chart for Saturday, February, 25, 2017

Institutional Ownership Chart

Institutional Ownership by Quarter for Amicus Therapeutics (NASDAQ:FOLD)

Earnings History Chart

Earnings by Quarter for Amicus Therapeutics (NASDAQ:FOLD)

Dividend History Chart

Dividend Payments by Quarter for Amicus Therapeutics (NASDAQ:FOLD)

Last Updated on 2/25/2017 by Staff